Video

Making Decisions on Bladder Removal

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of doctor.
Image of man.
Bladder preservation for bladder cancer requires balancing clinical factors and patient health with a personalized treatment plan.
Image of doctor.
Image of man.
Image of man with black hair.
Image of man.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Image of man with black hair.
Related Content
Image of clinical trial.
July 7th 2025

New Trials Target Brain, Bladder, Ovarian and Other Cancers

Spencer Feldman
New clinical trials are advancing in hard-to-treat cancers, offering targeted and less toxic options for patients with limited treatment paths.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Graphic that reads "FDA APPROVED" resembling a stamp of approval
June 12th 2025

FDA Approves UGN-102 For Some With Bladder Cancer

Bridget Hoyt
The FDA has granted approval to UGN-102 for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.
cancer horizons podcast logo
December 20th 2023

FDA Approves 3 Treatments, Cancer Vaccine Shows Promise

Alex Biese Brielle Benyon
The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.
Dr. Guru Sonpavde discusses the CheckMate 901 trial evaluating Opdivo plus Yervoy for those with cisplatin-ineligible, metastatic urothelial carcinoma.
June 2nd 2025

Breaking Down the CheckMate 901 Trial Data for Metastatic Bladder Cancer

Dr. Guru Sonpavde
Dr. Guru Sonpavde discusses the CheckMate 901 trial evaluating Opdivo plus Yervoy for those with cisplatin-ineligible, metastatic urothelial carcinoma.
Antihistamines may be associated with survival improvement in patients with metastatic urothelial carcinoma receiving Tecentriq: © stock.adobe.com
May 30th 2025

Additive Antihistamines May Improve Metastatic Bladder Cancer Outcomes

Alex Biese
Antihistamines may be associated with survival improvement in patients with metastatic urothelial carcinoma receiving Tecentriq.